-
2024-515593-27-00
5
2025-05-08
relapsed or refractory mantle cell lymphoma (R/R MCL)
-
2023-508773-82-00
5
2025-05-06
Stage IIB-IIIB (N2) resectable non small cell lung cancer
-
2024-515162-13-00
5
2025-04-29
Eosinophilic Asthma
-
2023-506206-38-00
4
2025-04-09
Diffuse Large B-cells non-Hodgkin Lymphoma
-
2023-504904-26-00
5
2025-04-07
Progressive Pulmonary Fibrosis
-
2024-513285-19-00
1
2025-03-14
Pancreatic Ductal Adeno Carcinoma
-
2024-514594-21-00
5
2025-03-13
Heterozygous Familial Hypercholesterolemia
-
2023-506288-33-00
9
2025-03-03
Metastatic castration resistant prostate cancer (mCRPC)
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2024-515020-36-00
9
2025-02-24
Advanced Solid tumour
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-516440-25-00
1
2025-02-06
KRAS G12D-mutant solid tumors.
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2024-512900-20-00
7
2025-01-30
Non-muscle invasive bladder cancer (NMIBC)
-
2024-515934-34-00
6
2025-01-28
Low-cardiac output syndrome (LCOS)
-
2024-511945-20-00
4
2025-01-24
patients affected by small cell lung cancer (SCLC)
-
2024-516842-21-00
5
2025-01-09
Recurrent ovarian cancer
-
2024-519481-44-00
4
2025-01-08
colorectal metastatic cancer
-
2024-516450-21-00
6
2024-12-31
metastatic or locally advanced urothelial cancer
-
2023-505204-34-00
1
2024-12-30
Mature B-Cell Neoplasm,
Non-Hodgkin Lymphoma,
Diffuse large B-cell lym
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2024-516839-27-00
4
2024-12-09
BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
-
2024-517820-21-00
4
2024-11-29
cystic fibrosis associated to persistent Staphylococcus aureus (includ